SCHEMBL31229566

SCHEMBL31229566

Cc1ccc(-c2cc3[nH]c(=O)c(C(=O)NC4C=CS(=O)(=O)C4)cc3s2)cc1C

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
TP53 P04637 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
JAK2 O60674 1/20 0.39
POLB P06746 2/20 0.31
PABPC1 P11940 1/20 0.31
CTDSP1 Q9GZU7 1/20 0.31
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
TSHR P16473 1/20 0.31
DYRK1A Q13627 1/20 0.31
DYRK1B Q9Y463 1/20 0.31
SMYD3 Q9H7B4 1/20 0.30
HSD17B1 P14061 1/20 0.30
HSD17B2 P37059 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31229581 0.87 LMNA (0.49) LMNAKMT2AMEN1TP53SMN1; SMN2
SCHEMBL31229571 0.82 MEN1 (0.41) LMNAKMT2AMEN1TP53SMN1; SMN2
SCHEMBL25149514 0.80 LMNA (0.44) LMNAKMT2AMEN1TP53SMN1; SMN2
SCHEMBL30364647 0.80 LMNA (0.44) LMNAKMT2AMEN1TP53SMN1; SMN2
SCHEMBL31229507 0.79 LMNA (0.40) LMNAKMT2AMEN1TP53SMN1; SMN2
SCHEMBL31229637 0.78 LMNA (0.40) LMNAKMT2AMEN1TP53SMN1; SMN2
SCHEMBL31229569 0.78 JAK2 (0.37) LMNAKMT2AMEN1TP53SMN1; SMN2
SCHEMBL31547518 0.77 LMNA (0.41) LMNAKMT2AMEN1TP53SMN1; SMN2
SCHEMBL31229597 0.77 LMNA (0.39) LMNAKMT2AMEN1TP53SMN1; SMN2
SCHEMBL31229553 0.77 MEN1 (0.40) LMNAKMT2AMEN1TP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024222866-A1 CYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF DANATLAS PHARMACEUTICALS CO., LTD. (CN) 2024-10-31 WO disclosed